laboratorios farmaceuticos r (41L) Details

Laboratorios Farmacéuticos ROVI, S.A. engages in the research, development, in licensing, manufacturing, and marketing of small molecule and specialty biologic drugs in Spain and internationally. Its principal product includes Bemiparin, a low molecular weight heparin. The company’s prescription products comprise Hibor to prevent thromboembolic disease; Osseor to treat post-menopausal osteoporosis; Hepadren for the prevention of clotting in the extracorporeal circuit; Pneumovax-23, a vaccine for immunization against pneumococcal illness; Glufan for relieving symptoms of degenerative osteoarthritis; and Corlentor for treating chronic stable angina pectoris. Its prescription products also include Exxiv for relieving the symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylarthritis, and acute gouty arthritis; Calcio y Vitamina D3 ROVI to treat osteoporosis; Bertanel to treat adults active rheumatoid, juvenile idiopatic, and psoriatic arthritis; Vytorin for patients with primary hypercholesterolaemia or mixed hyperlipidaemia; Absorcol for patients with hypercholesterolaemia and phytosterolaemia; and Thymanax for treating depressive episodes in adults. In addition, the company offers diagnostic products, such as SonoVue contrast medium for use with ultrasound imaging; and Iopamiro and Iomeron contrast media for diagnosis by computed tomography; and Multihance And Prohance for use in diagnostic magnetic resonance imaging, as well as OTC products comprising Perspirex to control sweating from the armpits; Enerzone, a protein product; Dentimelo to repair oral mucosal lesions and gums; and ColdPack cold and hot bag for reliving pain. Further, it distributes products licensed from other laboratories. The company was founded in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmacéuticos ROVI, S.A. is a subsidiary of Inversiones Clidia, S.L.

laboratorios farmaceuticos r (41L) Top Compensated Officers